Oric Pharmaceuticals, Inc.

Item 5. Other Information.

Securities Trading Arrangements of Directors and Executive Officers

During the last fiscal quarter, certain directors and officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:

On May 26, 2026, Dominic Piscitelli, our Chief Financial Officer, adopted a “Rule 10b5-1 trading arrangement” providing for the sale from time to time of an aggregate of up to 200,600 shares of our common stock and any unsold shared of common stock from Mr. Piscitelli’s prior 10b5-1 trading plan. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c) of the Exchange Act. The duration of the trading arrangement is from August 26, 2026, until June 1, 2027, or earlier if all transactions under the trading arrangement are completed.

On June 17, 2026, Mardi Dier, a member of our Board of Directors, adopted a “Rule 10b5-1 trading arrangement” providing for the sale from time to time of an aggregate of up to 114,383 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c) of the Exchange Act. The duration of the trading arrangement is from September 30, 2026, until June 30, 2027, or earlier if all transactions under the trading arrangement are completed.

Except as described above, no officers or directors, as defined in Rule 16a-1(f) of the Exchange Act, adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408, during the last fiscal quarter.